Literature DB >> 7499888

Clinical correlates and substrate specificities of antibodies exhibiting neutrophil nuclear reactivity--a methodological study.

B Bang la Cour1, A Wiik, M Høier-Madsen, B Baslund.   

Abstract

In a serological laboratory with a routine service for determining autoantibodies to human neutrophils, antibodies giving a selective or preferential reaction with the nucleus or perinuclear area of neutrophils are not uncommon. The aim of this study was to look for clinical correlates with the presence of such neutrophil-reactive autoantibodies. The specificity of such antibodies for nuclear or cytoplasmic antigens was studied in 65 consecutive sera displaying nuclear/perinuclear reactivity at a titre of at least 80 using the indirect immunofluorescence technique (IIF) on ethanol-fixed leucocytes. The sera were also investigated by IIF on formalin-acetone fixed leucocytes and on HEp-2 cells. ELISA techniques were used to measure antibodies to azurophil granule constituents (ANCA), purified myeloperoxidase (MPO-ANCA), and lactoferrin (LF-ANCA). Furthermore a qualitative spot immunoassay was used for the detection of antibodies to alpha, beta, and gamma fractions, and the nuclear fraction of neutrophils, purified proteinase 3 (PR3), MPO, enolase, lysozyme, elastase, lactoferrin, and cathepsin G. The diagnoses linked to such GS-ANA/pANCA positivity were arthritides, vasculitides, inflammatory bowel disease and chronic hepatic conditions. MPO was the main antigen recognized in the vasculitis group, but apart from that, rather limited antigen reactivity was demonstrable by these techniques, lysozyme being the most frequently recognized autoantigen in patients with arthritides. Human lymphocytes served as a suitable control substrate when distinguishing between GS-ANA/pANCA and ANA, whereas HEp-2 cells usually could not be used if both classes of antibodies were present in a sample. Furthermore, formalin-acetone fixation is not recommended for routine use.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499888     DOI: 10.1016/0022-1759(95)00196-7

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  8 in total

1.  Pitfalls of formalin fixation for determination of antineutrophil cytoplasmic antibodies.

Authors:  S M Chowdhury; V Broomhead; G P Spickett; R Wilkinson
Journal:  J Clin Pathol       Date:  1999-06       Impact factor: 3.411

2.  Autoantibodies to molecular targets in neutrophils in patients with ulcerative colitis.

Authors:  J Brimnes; O H Nielsen; A Wiik; N H Heegaard
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

Review 3.  Methods for the detection of anti-neutrophil cytoplasmic antibodies. Recommendations for clinical use of ANCA serology and laboratory efforts to optimize the informative value of ANCA test results.

Authors:  A Wiik
Journal:  Springer Semin Immunopathol       Date:  2001

4.  pANCA antibodies in patients with anterior uveitis: identification of a marker antibody usually associated with ulcerative colitis.

Authors:  L K Gordon; M Eggena; G N Holland; J M Weisz; J Braun
Journal:  J Clin Immunol       Date:  1998-07       Impact factor: 8.317

Review 5.  Neutrophil functions of patients with vasculitis related to myeloperoxidase-specific anti-neutrophil antibody.

Authors:  K Suzuki
Journal:  Int J Hematol       Date:  2001-08       Impact factor: 2.490

6.  A review of immunofluorescent patterns associated with antineutrophil cytoplasmic antibodies (ANCA) and their differentiation from other antibodies.

Authors:  J A Savige; B Paspaliaris; R Silvestrini; D Davies; T Nikoloutsopoulos; A Sturgess; J Neil; W Pollock; K Dunster; M Hendle
Journal:  J Clin Pathol       Date:  1998-08       Impact factor: 3.411

7.  Specificities of anti-neutrophil autoantibodies in patients with rheumatoid arthritis (RA).

Authors:  J Brimnes; P Halberg; S Jacobsen; A Wiik; N H Heegaard
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

Review 8.  Autoantibodies in vasculitis.

Authors:  Allan Wiik
Journal:  Arthritis Res Ther       Date:  2003-04-09       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.